The Integration of Palliative Care and Oncology: the Evidence

被引：0
作者：
Von Roenn, Jamie H. [1 ,2 ]
Temel, Jennifer [3 ]
机构：
[1] Northwestern Univ, NW Mem Hosp, Home Hosp Program, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, NW Mem Hosp, Home Hosp Program, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
来源：
ONCOLOGY-NEW YORK | 2011年 / 25卷 / 13期
关键词：
CELL LUNG-CANCER; QUALITY-OF-LIFE; SUPPORTIVE CARE; RANDOMIZED-TRIAL; PHASE-III; PLUS; CHEMOTHERAPY; GEMCITABINE; IMPROVEMENT; MANAGEMENT;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cancer care and palliative care each require a complex multi- and interdisciplinary approach to maximize the care of people with cancer. Recommendations for cancer treatment should both relieve the symptoms of cancer and prevent and treat side effects of anticancer therapy. Unrelieved symptoms not only contribute to worse quality of life but also can reduce a patient's ability to tolerate cancer therapy and may have a negative impact on survival. Consistent integration of palliative care practices into standard oncology care is needed across the trajectory of the cancer experience. This article will review the overlap between palliative care and oncology and discuss the available evidence that true integration of palliative and oncology care provides patients with optimal oncology care.
引用
收藏
页码：1258 / +
页数：6
相关论文
共 25 条
[1]  
American Society of Clinical Oncology, ASCO MULT CANC MAN C
[2]   Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].
Anderson, H. ;
Hopwood, P. ;
Stephens, R. J. ;
Thatcher, N. ;
Cottier, B. ;
Nicholson, M. ;
Milroy, R. ;
Maughan, T. S. ;
Falk, S. J. ;
Bond, M. G. ;
Burt, P. A. ;
Connolly, C. K. ;
McIllmurray, M. B. ;
Carmichael, J. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453
[3]  
[Anonymous], CANC FACTS FIG
[4]   Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].
Bezjak, Andrea ;
Tu, Dongsheng ;
Seymour, Lesley ;
Clark, Gary ;
Trajkovic, Aleksandra ;
Zukin, Mauro ;
Ayoub, Joseph ;
Lago, Sergio ;
de Albuquerque Ribeiro, Ronaldo ;
Gerogianni, Alexandra ;
Cyjon, Arnold ;
Noble, Jonathan ;
Laberge, Francis ;
Chan, Raymond Tsz-Tong ;
Fenton, David ;
von Pawel, Joachim ;
Reck, Martin ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3831-3837
[5]  
Boland A, BEST SUPPORTIVE CARE
[6]  
Buss Mary K, 2007, J Support Oncol, V5, P237
[7]   Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial [J].
Cella, D ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Heyes, A ;
Ochs, JS ;
Wolf, MK ;
Kay, AC ;
Kris, MG ;
Natale, RB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2946-2954
[8]   TRIALS WITH MITOMYCIN, IFOSFAMIDE AND CISPLATIN IN NONSMALL CELL LUNG-CANCER [J].
CULLEN, MH .
LUNG CANCER, 1995, 12 :S95-S106
[9]  
El-Jawahri Areej, 2011, J Support Oncol, V9, P87
[10]   SYMPTOM RELIEF WITH MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER [J].
ELLIS, PA ;
SMITH, IE ;
HARDY, JR ;
NICOLSON, MC ;
TALBOT, DC ;
ASHLEY, SE ;
PRIEST, K .
BRITISH JOURNAL OF CANCER, 1995, 71 (02) :366-370
123